- $20.02bn
- $19.13bn
- $1.70bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.75 | ||
| Price to Tang. Book | 16.75 | ||
| Price to Free Cashflow | 340.76 | ||
| Price to Sales | 11.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.88% | ||
| Return on Equity | -19.42% | ||
| Operating Margin | -13.1% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 391 | 625.49 | 820.22 | 1,082.57 | 1,696.91 | 1,920.65 | 2,274.55 | 41.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Directors
- Matthew Rabinowitz CHM (48)
- Steven Chapman PRE (42)
- Jonathan Sheena CFD (48)
- Michael Brophy CFO (41)
- Robert Schueren COO (59)
- Roelof Botha LED (48)
- Roy Baynes IND (66)
- Monica Bertagnolli IND (62)
- Rowan Chapman IND (50)
- Todd Cozzens IND (65)
- James Healy IND (56)
- Gail Marcus IND (64)
- Herman Rosenman IND (73)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 26th, 2007
- Public Since
- July 2nd, 2015
- No. of Shareholders
- 20
- No. of Employees
- 4,424
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 135,186,184
- Address
- 13011 MCCALLEN PASS, AUSTIN, 78753
- Web
- https://www.natera.com/
- Phone
- +1 6502499090
- Contact
- Michael Brophy
- Auditors
- Ernst & Young LLP
Upcoming Events for NTRA
Natera Inc Annual Shareholders Meeting
Q2 2025 Natera Inc Earnings Release
Similar to NTRA
Acadia Healthcare
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
Aveanna Healthcare Holdings
NASDAQ Global Select Market
FAQ
What is the Natera share price?
As of Today at 22:11 UTC, shares in Natera are trading at $148.08. This share price information is delayed by 15 minutes.
How has the Natera share price performed this year?
Shares in Natera last closed at $148.08 and the price had moved by +63.93% over the past 365 days. In terms of relative price strength the Natera share price has outperformed the S&P500 Index by +54.14% over the past year.
What are the analyst and broker recommendations for Natera?
The overall consensus recommendation for Natera is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Natera dividend yield?
Natera does not currently pay a dividend.
Does Natera pay a dividend?
Natera does not currently pay a dividend.
When does Natera next pay dividends?
Natera does not currently pay a dividend.
How do I buy Natera shares?
To buy shares in Natera you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Natera?
As of the previous close price of $148.08, shares in Natera had a market capitalisation of $20.02bn.
Where are Natera shares listed?
Here are the trading details for Natera:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NTRA
What kind of share is Natera?
Based on an overall assessment of its quality, value and momentum Natera is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Natera share price forecast for 2025?
The analyst consensus target price for shares in Natera is $196.05. That is 32.39% above the last closing price of $148.08.
Analysts covering Natera currently have a consensus Earnings Per Share (EPS) forecast of -$2.16 for the next financial year.
Find out moreWhat is the trend in the Natera share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Natera. Over the past six months, its share price has outperformed the S&P500 Index by +34.06%.
As of the last closing price of $148.08, shares in Natera were trading +5.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Natera PE Ratio?
The Natera PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $148.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Natera?
Natera's management team is headed by:
- Matthew Rabinowitz - CHM
- Steven Chapman - PRE
- Jonathan Sheena - CFD
- Michael Brophy - CFO
- Robert Schueren - COO
- Roelof Botha - LED
- Roy Baynes - IND
- Monica Bertagnolli - IND
- Rowan Chapman - IND
- Todd Cozzens - IND
- James Healy - IND
- Gail Marcus - IND
- Herman Rosenman - IND